SCHEMBL723605

SCHEMBL723605

Cc1cncc(C)c1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL18189392 0.97 UHRF1 (0.35)
SCHEMBL23927465 0.81
SCHEMBL29027121 0.77 NQO2 (0.38)
SCHEMBL21719110 0.77 GABRA1 (0.30)
SCHEMBL20844136 0.77 GABRA1 (0.32)
SCHEMBL21596955 0.75 CYP11B1 (0.35)
SCHEMBL30374480 0.75 CYP11B1 (0.35)
SCHEMBL31175983 0.73
SCHEMBL2921029 0.73
SCHEMBL14351961 0.72 LMNA (0.39)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 382 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026090602-A1 PIGMENTED RESIN AND CATALYST COMPOSITIONS MATERIA, INC. (US) 2026-04-30 WO disclosed
US-12600728-B2 Interleukin-17 inhibitors NOVARTIS AG (CH) 2026-04-14 US disclosed
EP-3110862-B1 ADHESION PROMOTER COMPOSITIONS FOR CYCLIC OLEFIN RESIN COMPOSITIONS ExxonMobil Product Solutions Company (US) 2026-04-01 EP disclosed
EP-3773573-B1 ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) MORPHIC THERAPEUTIC INC (US) 2026-03-18 EP disclosed
EP-4344702-B1 PYRAZOLYL DERIVATIVES USEFUL AS ANTI-CANCER AGENTS NOVARTIS AG (CH) 2026-01-28 EP disclosed
EP-4683900-A2 ROMP AND THERMAL INSULATION COMPOSITIONS AND MATERIALS AND USE THEREOF Materia, Inc. (US) 2026-01-28 EP disclosed
WO-2025245037-A1 CYCLIC OLEFIN COMPOSITIONS, ROMP COMPOSITIONS THEREOF, AND APPLICATIONS THEREOF MATERIA, INC. (US) 2025-11-27 WO disclosed
EP-4194092-B1 SYNTHESIS AND CHARACTERIZATION OF METATHESIS CATALYSTS UMICORE AG & CO KG (DE) 2025-10-22 EP disclosed
EP-2970522-B1 IN-MOLD COATING OF ROMP POLYMERS MATERIA INC (US) 2025-05-21 EP disclosed
US-12291523-B2 LXR modulators with bicyclic core moiety ORSOBIO, INC. (US) 2025-05-06 US disclosed
US-6747023-B1 INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-06-08 US disclosed
US-20040082611-A1 Anticoagulants; brain disorders; respiratory system disorders; side effect reduction DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2004-04-29 US disclosed
WO-2004013198-A2 SYNTHESIS OF MACROCYCLIC POLYMERS BY RING INSERTION POLYMERIZATION OF CYCLIC OLEFIN MONOMERS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2004-02-12 WO disclosed
US-20030236427-A1 Cross-metathesis of olefins directly substituted with an electron-withdrawing group using transition metal carbene catalysts NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-12-25 US disclosed
WO-2003087167-A2 CROSS-METATHESIS OF OLEFINS DIRECTLY SUBSTITUTED WITH AN ELECTRON-WITHDRAWING GROUP USING TRANSITION METAL CARBENE CATALYSTS CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2003-10-23 WO disclosed
US-20020173527-A1 Substituted azabicyclic compounds ASTLES PETER CHARLES (GB) 2002-11-21 US disclosed
US-6303600-B1 USED IN THERAPY OF DISEASE STATES ASSOCIATED WITH PROTEINS THAT MEDIATE CELLULAR ACTIVITY RHONE-POULENC RORER LIMITED (GB) 2001-10-16 US disclosed
EP-1104754-A1 NOVEL SULFONYL DERIVATIVES DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2001-06-06 EP disclosed
EP-0934307-A1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE RHONE-POULENC RORER LIMITED (GB) 1999-08-11 EP disclosed
WO-1997048697-A1 SUBSTITUTED AZABICYLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF THE PRODUCTION OF TNF AND CYCLIC AMP PHOSPHODIESTERASE RHONE-POULENC RORER LIMITED (GB) 1997-12-24 WO disclosed